170 related articles for article (PubMed ID: 36530994)
1.
Chu YD; Liu HF; Chen YC; Chou CH; Yeh CT
Front Oncol; 2022; 12():996820. PubMed ID: 36530994
[TBL] [Abstract][Full Text] [Related]
2. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
4. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
Lin CC; Hsu CW; Chen YC; Chang ML; Liang KH; Lai MW; Lin CL; Chien RN; Lin KH; Yeh CT
Pharmacogenomics J; 2020 Feb; 20(1):57-68. PubMed ID: 31611591
[TBL] [Abstract][Full Text] [Related]
5. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
[TBL] [Abstract][Full Text] [Related]
7. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT
Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Qin S; Ryoo BY; Lu SN; Yen CJ; Feng YH; Lim HY; Izzo F; Colombo M; Sarker D; Bolondi L; Vaccaro G; Harris WP; Chen Z; Hubner RA; Meyer T; Sun W; Harding JJ; Hollywood EM; Ma J; Wan PJ; Ly M; Bomalaski J; Johnston A; Lin CC; Chao Y; Chen LT
Ann Oncol; 2018 Jun; 29(6):1402-1408. PubMed ID: 29659672
[TBL] [Abstract][Full Text] [Related]
9. Association of WWOX rs9926344 polymorphism with poor prognosis of hepatocellular carcinoma.
Chen W; Zhou C; Zhang W; Atyah M; Yin Y; Guo L; Tang W; Dong Q; Ye Q; Ren N
J Cancer; 2018; 9(7):1239-1247. PubMed ID: 29675105
[No Abstract] [Full Text] [Related]
10. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells.
Chu YD; Fan TC; Lai MW; Yeh CT
Cell Death Dis; 2022 Nov; 13(11):956. PubMed ID: 36376274
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
[TBL] [Abstract][Full Text] [Related]
13. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
[TBL] [Abstract][Full Text] [Related]
14. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
Chen WT; Lin SM; Lee WC; Wu TJ; Lin CC; Shen CH; Chang ML; Lin CL; Yeh CT
Hepatol Int; 2022 Feb; 16(1):148-158. PubMed ID: 34982369
[TBL] [Abstract][Full Text] [Related]
15. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
Gupta S; Sahu D; Bomalaski JS; Frank I; Boorjian SA; Thapa P; Cheville JC; Hansel DE
Endocr Pathol; 2018 Sep; 29(3):236-241. PubMed ID: 29453600
[TBL] [Abstract][Full Text] [Related]
16. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
17. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
18. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.
Sahu D; Gupta S; Hau AM; Nakashima K; Leivo MZ; Searles SC; Elson P; Bomalaski JS; Casteel DE; Boss GR; Hansel DE
Am J Pathol; 2017 Jan; 187(1):200-213. PubMed ID: 27979310
[TBL] [Abstract][Full Text] [Related]
19. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
